Adaptive mutability of colorectal cancers in response to targeted therapies
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
A cross-kingdom tale of drug resistance: Physicians who treat bacterial infections and those who treat cancer often face a common challenge: the development of drug resistance. It is well known that when bacteria are exposed to antibiotics, they temporarily increase their mutation rate, thus increasing the chance that a descendant antibiotic-resistant cell will arise. Russo et al. now provide evidence that cancer cells exploit a similar mechanism to ensure their survival after drug exposure (see the Perspective by Gerlinger). They found that human colorectal cancer cells treated with certain targeted therapies display a transient up-regulation of errorprone DNA polymerases and a reduction in their ability to repair DNA damage. Thus, like bacteria, cancer cells can adapt to therapeutic pressure by enhancing their mutability. Science , this issue p. 1473 ; see also p. 1458
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This observation may be due to a more potent treatment effect with the combination of divarasib and cetuximab imposing a stronger selective pressure and/or potentially increasing the adaptive mutability of the residual cancer cells30.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [30]
Citations
Cites
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
GENCODE: The reference human genome annotation for The ENCODE Project
Harrow, J., Frankish, A., Gonzalez, J. M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B. L., Barrell, D., Zadissa, A., Searle, S., et al. (2012) · Genome Research · doi:10.1101/gr.135350.111 · Cited by 4,585
Mutations of bacteria from virus sensitivity to virus resistance
Luria, S. E., & Delbrück, M. (1943) · Genetics · doi:10.1093/genetics/28.6.491 · Cited by 3,894
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
Self-citationThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Cited by
Items 401–435 of 435
Popovic, M., Talarico, O. S., van den Hoff, J., Kunin, H. S., Zhang, Z., Lafontaine, D., Dogan, S., Leung, J., Kaye, E., Czmielewski, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13279805
Trigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Figshare · doi:10.6084/m9.figshare.26713885
Trigos, A., Bongiovanni, F., Zhang, Y., Zethoven, M., Tothill, R. W., Pearson, R. B., Papenfuss, A. T., & Goode, D. L. (2024) · Figshare · doi:10.6084/m9.figshare.26713882
Lu, Y., Jiang, Z., Wang, K., Yu, S., Hao, C., Ma, Z., Fu, X., Qin, M. Q., Xu, Z., & 范列英 (2022) · Figshare · doi:10.6084/m9.figshare.20408638
Adaptive plasticity in targeted therapy
Amodio, V., Patelli, G., & Bardelli, A. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.12.007
Self-citationBeyond the Burden: Elevating Immunotherapy in Colorectal Cancer
Parseghian, C. M., & Eluri, M. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4251
“Excluded phenotypes” restrict genetic paths toward adaptation in declining populations
Andon, J. S., Kocher, C. D., Dill, K. A., & Wang, T. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507223123
“…observed in many organisms, from bacteria (34, 40–46), to yeast ( Saccharomyces cerevisiae ) (47–49), algae ( Chlamydomonas reinhardtii ) (50), fruit flies ( Drosophila melanogaster ) (51), nematodes ( Caenorhabditis briggsae and Caenorhabditis elegans ) (52, 53), and even human cancer (54, 55).”
Targeted Therapy-Induced Chromosomal Instability Dictates Mitotic Dependency on Aurora Kinase APreprint
Li, C., Nangia, V., Vieira, M. D., Nimbalkar, A., Graser, C. J., Chang, J. B., Syed, M. U., Shen, Y., Koranne, R., Zou, L., et al. (2026) · SSRN Electronic Journal · doi:10.64898/2026.01.22.701085
Third-line and beyond treatment in mCRC and sequencing
Maurel, J., & Piedra, M. R. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00130
Lin, X., Wu, C., Wu, D., Qin, W., Zeng, Y., Song, Y., Li, X., Shim, J. S., Liu, S. D., & Li, A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07760-8 · Cited by 2
“Although targeted therapies have introduced new treatment strategies and improved outcomes for certain patients, significant challenges remain—particularly the loss of tumor suppressor gene expression, often referred to as “undruggable targets” [2].”
Oleynik, V., Kadangodan, A. E., Gahramanov, V., Das, S. R., Levi, B., Yaglom, J. A., Аношкин, К. И., Kumar, S., Steinberg, B. G., Reizel, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.20.707073
Fountzilas, C. K., Rosario, S. R., Witkiewicz, A. K., Withers, H. G., Bajor, D. L., Mukherjee, S., Saltzman, J. N., Maguire, O., Minderman, H., Chatley, S., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70434 · Cited by 1
“39 It is plausible that p53 mt tumors are more prone to adaptive mutability when treated with EGFR mAbs leading to improved outcomes when these agents are used in combination with immune checkpoint inhibitors.”
MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy
Carpenter, C., Simmons, N., Davis, W. J. H., Thompson, M., van Zandwijk, N., Drummond, C. J., & Reid, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062701
Xiao, D., Yao, J., Yang, X., Xie, Y., Zhou, X., Li, D., Peng, M., Wang, W., Zou, H., & Yang, X. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08556-w
“Although cetuximab also downregulated the expression of BRCA2 and Rad51 at the IC 50 concentration, its effect is signi fi cantly weaker than that of 4C (Supplementary Fig.”
Biomimetic Nanoparticles for Bone Regeneration: Construction Strategies and Therapeutic Mechanisms
Wang, Z., Shen, N., Yang, T., Dong, S., Kaige, X., Zhao, K., Zhang, Y., Jiang, Y., & Li, T. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s589003 · Cited by 2
“137,138 Exploiting these features, nanoparticles cloaked with tumor cell membranes can achieve active targeting and selective adhesion to tumor tissues, thereby improving drug delivery efficiency and antitumor efficacy.”
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
Origin and pronostic impact of intra-leukemic heterogeneity in acute myeloid leukemias
Duchmann, M. (2022) · theses.fr (ABES) · doi:10.70675/74f56644z3676z489bz8e12z27fa072401b7
Huismans, M. A., Gort, E. H., van der Heijden, L. T., Mese, S. M. G., Wolterink, H. M. K., Braat, M. N. G. J. A., Elias, S. G., Vos, F. D., Devriese, L. A., Verheul, H. M. W., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03398-x · Cited by 2
“This strategy has been more effective than single-agent MAPK inhibition, particularly in CRC [8 – 11].”
IL-1-mediated inflammation promotes metastatic dissemination and resistance to EGFR-targeted therapy
Pagano, F., Girone, C., Borrelli, F., Romaniello, D., Gelfo, V., Filippini, D. M., Morselli, A., Mazzeschi, M., Querzoli, G., Ambrosi, F., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01389-y
“These fi ndings are consistent with previous observations reported by Russo et al. in colorectal cancer models 24 .”
Non-genetic regulation of chemopersistence in Triple Negative Breast Cancers
Baudre, L. (2024) · theses.fr (ABES) · doi:10.70675/6422f0bbza832z4dcfza920zaa55605f8a31
Mangogna, A., Sabella, G., & Milione, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1814001
“Accumulating evidence of shared clonal origins (3, 6, 15), plasticity mechanisms (16 – 18), and potential prognostic impact (9) suggests that neuroendocrine differentiation represents a spectrum within colorectal tumour evolution rather than a strictly separate entity.”
Su, Y., Liu, C., Lu, X., Chuang, H.-Y., Li, G., Shao, S., Kong, Y., Lee, J. W., Ng, R. H., Wong, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71349-4 · Cited by 14
“The drug dosages and treat-ment conditions used for HCC827 and HT-29 cells to generate DTPs were based on previous studies 4,42 .”
InfluentialDavis, W. J. H., Thompson, M., Farry, S. M., McKinney, C., Gimenez, G., Hatley, M. E., Kumar, R., Rodger, E. J., Chatterjee, A., Diermeier, S. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723110
“We then performed a plasmid-based HR assay 12,47 to investigate whether knockdown of MALAT1 or NEAT1 has functional implications on HR capacity in DTPs 12,47 .”
InfluentialWEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer
Buzo, K., Bizzozero, L., Lentini, M., Opattová, A., Suárez, B. H., Torres, M., Chiabotto, G., Nisticò, C., Lazzari, G. D., Zanella, E. R., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00434-4 · Cited by 1
“…and other MAPK pathway inhibitors, resistance inevitably emerges through various pre-existing or adaptive mechanisms (Di Nicolantonio et al, 2021; Russo et al, 2019), including genetic mutations, activation of alternative signaling pathways, metabolic reprogramming and phenotypic plasticity.”
Self-citationFauveau, C., Lawendy, E., Deforges, J., Cochin, S., Moreau, B., Balloul, J., Erbs, P., Jain, S., & LAVERNY, G. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201279
“8,77,78 However, whether the degree of persistence enrichment in MRD samples can predict resistance development in patients remains to be determined.”
Interaction of High-Dose Antioxidant Vitamin Supplements in Cancer Treatment: A Dou-ble Sword?
Samancı, M., & Ekici, E. M. (2026) · Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi · doi:10.37989/gumussagbil.1851762
Wang, H., Liu, S., Zhang, M., Deng, C., & Han, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1912866
Targeting EGFR in lung cancer: lessons in signal transduction and treatment-induced mutagenesis
Nieves, A. S., Daele, M. V., Konsker, H. B., & Yarden, Y. (2026) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2024.0512 · Cited by 1
DNA damage and repair: Future perspectives
Rajpurohit, Y. S., Mishra, A., Sharma, D. K., & Soni, I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-42857-9.00002-5
Liang, J., Liu, R., Liang, S., Wang, Z., & Zhao, H. (2026) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500177
Aceituno, L., Valenzi, E., Segatto, O., Saborowski, A. L., & Vogel, A. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.102619
Géraud, M., Gence, R., Casanova, A., Clermont, E., Salimbeni, S., Özsu, N., Vienne, M., Delahaye, C., Borrull, E., Lusque, A., et al. (2026) · Science Advances · doi:10.1126/sciadv.aeh9099
Reframing cancer therapy through tumor plasticity
Shah, A. M., Marsh, B., & de Sauvage, F. J. (2026) · Nature Cancer · doi:10.1038/s43018-026-01232-0
“…cancer and colorectal cancer (CRC) cells exposed to epidermal growth factor receptor (EGFR) or BRAF inhibitors transiently reprogram DNA repair pathways toward error-prone mechanisms, increasing the mutational burden and facilitating the acquisition of resistance-conferring mutations 24,25 (Fig.”
Zhang, J., Liu, Z., Zhao, J., Liu, X., 刘之英, Xue, H., Lin, T., & Zhu, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1906797
“This suppression of cellular defense mechanisms creates a permissive environment for the accumulation of genomic instability (Russo et al., 2019).”
Giri, S., Selvadurai, B. R., Gupta, N., Nieves, A. S., Genna, A., Lindzen, M., Chatterjee, R., Daele, M. V., Ramesh-Kumar, D., Zerbib, M., et al. (2026) · Advanced Science · doi:10.1002/advs.78290
“According to one model, TKI treated cells transiently increase their mutation rates to gain resistance [ 26 ].”
Metadata
- Authors
- Russo, M., Crisafulli, G., Sogari, A., Reilly, N. M., Arena, S., Lamba, S., Bartolini, A., Amodio, V., Magrì, A., Novara, L., Sarotto, I., Nagel, Z. D., Piett, C. G., Amatu, A., Sartore-Bianchi, A., Siena, S., Bertotti, A., Trusolino, L., Corigliano, M., Gherardi, M., Lagomarsino, M. C., Di Nicolantonio, F., & Bardelli, A.
- Affiliations
- Candiolo Cancer Institute (IT)
- Fondazione Piemontese per la Ricerca sul Cancro Onlus (IT)
- Harvard University (US)
- University of Milan (IT)
- Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
- Candiolo Cancer Institute, FPO–IRCCS, Candiolo (TO) 10060, Italy.
- Corresponding author
- Russo, Mariangela
- Bardelli, Alberto
- ORCID
- Russo, Mariangela
- Crisafulli, Giovanni
- Sogari, Alberto
- Reilly, Nicole M.
- Arena, Sabrina
- Lamba, Simona
- Bartolini, Alice
- Amodio, Vito
- Magrì, Alessandro
- Novara, Luca
- Sarotto, Ivana
- Nagel, Zachary D.
- Piett, Cortt G.
- Amatu, Alessio
- Sartore-Bianchi, Andrea
- Siena, Salvatore
- Bertotti, Andrea
- Trusolino, Livio
- Corigliano, Mattia
- Gherardi, Marco
- Lagomarsino, Marco Cosentino
- Di Nicolantonio, Federica
- Bardelli, Alberto
- Venue
- Science
- Published
- 2019-12-20
- Volume
- 366
- Issue
- 6472
- Pages
- 1473-1480
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2987148655
- Cited by
- 433
- References
- 62
- Citations by year
- 2026: 41 · 2025: 55 · 2024: 60 · 2023: 70 · 2022: 76 · 2021: 72 · 2020: 57 · 2019: 2
- FWCI
- 21.60
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- H2020 Health (635342-2 MoTriColor, no. 754923 COLOSSUS)
- Ministero della Salute (Ricerca Corrente 2019 RC2019)
- Associazione Italiana per la Ricerca sul Cancro (9970 Extension program, IG. 16788, ID. 21091, ID.21091, AIRC IG 2018 - ID. 21923)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, drug resistance, targeted therapy, EGFR inhibition, BRAF inhibition, DNA mismatch repair, homologous recombination, error-prone DNA polymerases, microsatellite instability, drug-tolerant persister cells, DNA damage, patient-derived xenografts
- MeSH terms
- Adaptation, Biological, Humans, Selection, Genetic, Colorectal Neoplasms, Down-Regulation, Mutagenesis, Drug Resistance, Neoplasm, Proto-Oncogene Proteins B-raf, DNA Mismatch Repair, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.